Scholarlink

<p>The current study aimed to conduct a phytochemical screening of commonly known <i>Withania somnifera</i> leaf extract through gas chromatography and mass spectrometry (GC–MS) to identify the bioactive compounds responsible for its MAO-A inhibitory action and evaluate the pharmacological potentialities of the extract and its fractions against anxiety. In the in-silico analysis, various tools were employed, including molecular docking and molecular dynamics (MD) simulation. These methods assessed the binding affinity and stability of the phytochemicals (ligands) with MAO-A. The preclinical efficacy and safety of the phytochemicals were evaluated using ADMET/T analysis. Furthermore, the biological activity of the selected phytochemicals as potential “MAO-A” inhibitors was assessed using PASS analysis. Lipinski’s rule of five was applied to predict the drug-likeness properties of the compounds. The interacting residues and the types of interactions between the active site of MAO-A and the compounds were evaluated. The cumulative results of these analyses identified 2-Methoxy-4-vinylphenol, Hexadecanoic acid, <i>N</i>,<i>N</i>-Bis(2-hydroxyethyl) dodecanamide, 1,2 Benzene dicarboxylic acid diethyl ester, and Oxacycloheptadec-8-en-2-one as hit compounds from <i>W. somnifera</i>, suggesting their potential as MAO-A inhibitors. This research aims to provide an elaborative description of promising phytochemical entities with activities against MAO-A. However, the efficacy of these phytochemicals as potential anxiolytic compounds needs further validation via in vitro and in vivo studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Investigating the anxiolytic potential of Withania somnifera: a GC–MS and in silico study targeting MAO-A inhibition

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月28日

查看全文
  • Moh Sajid Ansari,
  • Kashif Abbas,
  • Mudassir Alam,
  • Nazura Usmani,
  • Adnan Khan,
  • Abrar Ahmad Khan,
  • Kamel Hessini

摘要

The current study aimed to conduct a phytochemical screening of commonly known Withania somnifera leaf extract through gas chromatography and mass spectrometry (GC–MS) to identify the bioactive compounds responsible for its MAO-A inhibitory action and evaluate the pharmacological potentialities of the extract and its fractions against anxiety. In the in-silico analysis, various tools were employed, including molecular docking and molecular dynamics (MD) simulation. These methods assessed the binding affinity and stability of the phytochemicals (ligands) with MAO-A. The preclinical efficacy and safety of the phytochemicals were evaluated using ADMET/T analysis. Furthermore, the biological activity of the selected phytochemicals as potential “MAO-A” inhibitors was assessed using PASS analysis. Lipinski’s rule of five was applied to predict the drug-likeness properties of the compounds. The interacting residues and the types of interactions between the active site of MAO-A and the compounds were evaluated. The cumulative results of these analyses identified 2-Methoxy-4-vinylphenol, Hexadecanoic acid, N,N-Bis(2-hydroxyethyl) dodecanamide, 1,2 Benzene dicarboxylic acid diethyl ester, and Oxacycloheptadec-8-en-2-one as hit compounds from W. somnifera, suggesting their potential as MAO-A inhibitors. This research aims to provide an elaborative description of promising phytochemical entities with activities against MAO-A. However, the efficacy of these phytochemicals as potential anxiolytic compounds needs further validation via in vitro and in vivo studies.